38 Results for "

GTPγS binding

" in MedChemExpress (MCE) Product Catalog:
Products (38)

38 Results for "GTPγS binding" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-112461A
CAS No.: 627034-85-9
Purity:  97.39%
Target:  

P2X Receptor

Research Areas:  

Cardiovascular Disease

NF449 octasodium is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 octasodium is a G-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103364A
CAS No.: 1784252-84-1
Purity:  99.92%
Target:  

CCR

Research Areas:  

Inflammation/Immunology

C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-103364
CAS No.: 864289-85-0
Purity:  99.95%
Target:  

CCR

Research Areas:  

Inflammation/Immunology

C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111454
CAS No.: 2134602-45-0
Purity:  98.01%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120645
CAS No.: 313669-88-4
Purity:  99.90%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioid receptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ 35S]GTPγS binding in mouse brain membranes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103565
CAS No.: 97075-46-2
Purity:  99.83%
Target:  

mGluR

Research Areas:  

Neurological Disease

AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103565A
CAS No.: 83027-13-8
Purity:  98.37%
Target:  

mGluR

Research Areas:  

Neurological Disease

AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
loading...
    loading...
Cat. No.: HY-W140439
CAS No.: 19420-56-5
Synonyms: 18:1 Lyso PC
Target:  

Endogenous Metabolite

Research Areas:  

Inflammation/Immunology

1-Oleoyl-sn-glycero-3-phosphocholine (18:1 Lyso PC), a lysophospholipid, is a GPR82 inhibitor. 1-Oleoyl-sn-glycero-3-phosphocholine abrogates constitutive Gi-coupled GPR82 activity, shifts active/inactive equilibrium to inactive, suppresses Gi protein activation, increases cAMP production, and decreases GTPγS binding to Gαi proteins. 1-Oleoyl-sn-glycero-3-phosphocholine contributes to adipocyte lipolysis regulation.1-Oleoyl-sn-glycero-3-phosphocholine exhibits reduced serum levels in mouse models of steatohepatitis, linked to hepatic Lpcat 1-4 up-regulation .
loading...
    loading...
Cat. No.: HY-15799
CAS No.: 919351-41-0
Purity:  99.33%
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .
loading...
    loading...
Cat. No.: HY-107721
CAS No.: 217461-40-0
Purity:  98.59%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

(±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a Ki of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC50 value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ .
loading...
    loading...
Cat. No.: HY-12927
CAS No.: 1240494-13-6
Purity:  99.88%
Target:  

CXCR

Research Areas:  

Inflammation/Immunology

SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca 2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model .
loading...
    loading...
Cat. No.: HY-112461
CAS No.: 389142-38-5
Target:  

P2X Receptor

Research Areas:  

Cardiovascular Disease

NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a G-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
loading...
    loading...
Cat. No.: HY-122255
CAS No.: 353231-17-1
Purity:  98.92%
Target:  

mGluR

Research Areas:  

Neurological Disease

LY487379 is a selective human mGluR2 positive allosteric modulator (PAM). LY487379 potentiates glutamate-stimulated [ 35S]GTPγS binding with EC50 values of 1.7 μM and >10 μM for mGlu2 and mGlu3 receptors respectively. LY487379 promotes cognitive flexibility and facilitates behavioral inhibition in a rat model. LY487379 can be used for schizophrenia research .
loading...
    loading...
Cat. No.: HY-108656
CAS No.: 436847-09-5
Target:  

P2Y Receptor Arrestin

Research Areas:  

Cardiovascular Disease

MRS2365 is a potent and selective P2Y1 receptor (EC50=0.4 nM) /[ 35S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC50 of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors .
loading...
    loading...
Cat. No.: HY-P10495A
Target:  

Peptides

Research Areas:  

Cancer

GPR110 peptide agonist P12 acetate is the acetate salt form of GPR110 peptide agonist P12 (HY-P10495). GPR110 peptide agonist P12 acetateis a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 acetate can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 acetate mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 acetate can be used in the study of developmental disorders and cancers related to GPR110 .
loading...
    loading...
Cat. No.: HY-108656A
Purity:  ≥99.0%
Target:  

P2Y Receptor Arrestin

Research Areas:  

Cardiovascular Disease

MRS2365 trisodium is a potent and selective P2Y1 receptor (EC50=0.4 nM)/[ 35S]GTPγS binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity .
loading...
    loading...
Cat. No.: HY-118140
CAS No.: 1998197-39-9
Purity:  99.43%
ZCZ011 is a potent and brain-penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain .
loading...
    loading...
Cat. No.: HY-107401
CAS No.: 370893-06-4
Synonyms: SCH-351125
Target:  

HIV CCR Calcium Channel

Research Areas:  

Infection

Ancriviroc (SCH-351125) is an orally active CCR5 antagonist with an IC50 value of 13 nM against hCCR5. Ancriviroc specifically binds to hCCR5, blocks ligand-induced signal transduction, calcium influx, GTPγS binding, chemotaxis, ligand binding, and HIV-1 entry, induces conformational changes in CCR5, and inhibits infection and replication of R5-tropic HIV-1 .
loading...
    loading...
Cat. No.: HY-113667
CAS No.: 1032892-26-4
Purity:  99.61%
ASN04885796 (compound IV) is an GPR17 activator with an EC50 of 2.27 nM for GPR17 induced GTPγS binding. ASN04885796 has neuroprotective property and can be used for research of neurological diseases .
loading...
    loading...
Cat. No.: HY-128111
CAS No.: 483283-39-2
Purity:  99.21%
Research Areas:  

Neurological Disease

ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases .
loading...
    loading...